Colorectal cancer is the second most common and fatal cancer in Hong Kong. In 2019, it has recorded more than 5,000 cases of colorectal cancer have been recorded, accounting for 15.8% of all cancer cases.

Colorectal cancer is one of the cancers with the best chance of being detected early—up to 90 percent of patients can be treated when detected early. In fact, one of the five people had large intestine polyps. Although most polyps are benign, there is a risk of developing cancer. Therefore, polyp detection is one of the methods that can effectively prevent colorectal cancer. But according to 2017 data, nearly half of colorectal cancer cases are detected at an advanced stage, making treatment very difficult. Therefore, early detection is one of the most effective ways to prevent colorectal cancer. How does ColoClear work? The ColoClear kit includes two test tubes that each perform a different test. One test extracts the DNA from your stool, and tests against certain biomarkers indicative of the presence of colorectal cancer and/or pre-cancerous polyps. The other test is a standard Faecal Immunocolloid Test (FIT) that detects traces of blood in your stool, which can be indicative of colorectal cancer. The DNA test detects altered DNA such as mutations that can indicate pre-cancerous polyps and/or colorectal cancer. A Faecal Immunocolloid Test (FIT) tests for traces of blood, which can be caused by colorectal cancer and/or pre-cancerous polyps. However, polyps or growths that bleed may not bleed all the time. For this reason, the sensitivity of a FIT test for colorectal cancer ranges from 77% - 94% when compared to screening for colorectal cancer using a colonoscopy. The combination of these two tests increases the sensitivity for colorectal cancer detection to up to 96% by testing for multiple biomarkers.